International journal of antimicrobial agents · 2026
Comparative outcomes of daptomycin and linezolid in vancomycin-resistant enterococcal intra-abdominal infections with bacteraemia.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsai Tsung-Yu, Chuang Yu-Chung, Yang Jia-Ling, Lin Chi-Ying, Huang Sung-Hsi, Wang Jann-Tay, Chen Yee-Chun, Chang Shan-Chwen
Аннотация
OBJECTIVE: We set out to see if daptomycin or linezolid (8-12 mg/kg) is effective for vancomycin-resistant enterococci (VRE) intra-abdominal infections (IAIs) because of its efficacy for VRE bloodstream infections (BSIs).
METHODS: We conducted a multicentre observational study. Between April 2010 and October 2024, we screened all patients with VRE-BSIs and included those with a documented VRE-IAI treated with daptomycin or linezolid. Limiting enrolment to patients with concurrent bloodstream infections reduced misclassification bias. The primary outcome was 28‑day in‑hospital mortality.
RESULTS: Of the 184 patients included, 149 received daptomycin and 35 received linezolid. Most patients (98.3%) underwent source control procedures. A total of 96 patients (52.2%) had hepatobiliary IAI, while 88 (47.8%) had non-biliary IAI. The 28-day mortality did not differ significantly between the daptomycin and linezolid groups (29.5% vs. 37.1%; P = .42). Multivariable logistic regression identified independent predictors of mortality, including higher Pitt bacteraemia score (adjusted OR [95% CI], 1.22 [1.06-1.41]; P = .006), lower platelet count (0.97 [0.94-0.99]; P = .02), and malignancy (2.41 [1.10-5.25]; P = .03). Daptomycin was not associated with increased mortality compared with linezolid (adjusted OR [95% CI], 0.63 [0.28-1.44]; P = .27). Daptomycin ≥11 mg/kg was linked to reduced mortality (adjusted OR [95% CI], 0.29 [0.09-0.91]; P = .03), whereas daptomycin 8-11 mg/kg showed no significant difference (0.79 [0.34-1.85]; P = .59). Findings were consistent in an augmented inverse probability weighting analysis.
CONCLUSIONS: Daptomycin is comparable with linezolid for treating VRE-IAI and BSI, with daptomycin ≥11 mg/kg associated with improved survival. Further investigations are warranted given the small sample size.
METHODS: We conducted a multicentre observational study. Between April 2010 and October 2024, we screened all patients with VRE-BSIs and included those with a documented VRE-IAI treated with daptomycin or linezolid. Limiting enrolment to patients with concurrent bloodstream infections reduced misclassification bias. The primary outcome was 28‑day in‑hospital mortality.
RESULTS: Of the 184 patients included, 149 received daptomycin and 35 received linezolid. Most patients (98.3%) underwent source control procedures. A total of 96 patients (52.2%) had hepatobiliary IAI, while 88 (47.8%) had non-biliary IAI. The 28-day mortality did not differ significantly between the daptomycin and linezolid groups (29.5% vs. 37.1%; P = .42). Multivariable logistic regression identified independent predictors of mortality, including higher Pitt bacteraemia score (adjusted OR [95% CI], 1.22 [1.06-1.41]; P = .006), lower platelet count (0.97 [0.94-0.99]; P = .02), and malignancy (2.41 [1.10-5.25]; P = .03). Daptomycin was not associated with increased mortality compared with linezolid (adjusted OR [95% CI], 0.63 [0.28-1.44]; P = .27). Daptomycin ≥11 mg/kg was linked to reduced mortality (adjusted OR [95% CI], 0.29 [0.09-0.91]; P = .03), whereas daptomycin 8-11 mg/kg showed no significant difference (0.79 [0.34-1.85]; P = .59). Findings were consistent in an augmented inverse probability weighting analysis.
CONCLUSIONS: Daptomycin is comparable with linezolid for treating VRE-IAI and BSI, with daptomycin ≥11 mg/kg associated with improved survival. Further investigations are warranted given the small sample size.